Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 6/2019

21.01.2019

Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population

verfasst von: Regina Juanbeltz, Jesús Castilla, Iván Martínez-Baz, Aisling O’Leary, Maite Sarobe, Ramón San Miguel

Erschienen in: Quality of Life Research | Ausgabe 6/2019

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Purpose

To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting antivirals and a sex- and age-paired sample of the general population.

Methods

HRQoL was evaluated in patients recruited in Navarre, Spain, from May 2016 to April 2017 at baseline and after SVR, using the EQ-5D-5L questionnaire. Both results were compared to those of general population of the same sex and age obtained from the 2011/12 National Health Survey in Spain. Observed/expected (O/E) ratios for health dimensions and differences between O-E in EQ-5D utility and visual analogical scale (VAS) scores were calculated.

Results

206 patients were studied. Before treatment, patients had more problems than the general population in every domain of EQ-5D-5L, except in self-care dimension (O/E = 1.1). After SVR, patients continued having more limitation, especially for usual activities (O/E = 3.1), anxiety/depression (O/E = 2.8) and EQ-5D utility (− 0.086, p < 0.001); however, differences in VAS score between patients and general population disappeared (74.8 vs 76.5, p = 0.210). F0–F1 patients with SVR had minor differences with the general population in EQ-5D-5L dimensions, utility and VAS score. Although cirrhotic patients also reduced that difference, they still had worse HRQoL, especially in usual activities, self-care, EQ-5D utility (− 0.152, p < 0.001) and VAS score (− 8.5, p = 0.005).

Conclusions

HRQoL of chronic hepatitis C patients remains lower than that of the general population despite viral clearance, with primary problems in usual activities and anxiety/depression. Knowledge of these on-going problems despite cure serves to guide healthcare interventions and patient’s follow-up.
Vorheriger Artikel Using health-related quality of life to predict cardiovascular disease events
Nächster Artikel Modality transition on renal replacement therapy and quality of life of patients: a 10-year follow-up cohort study

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Degasperi, E., Aghemo, A., & Colombo, M. (2017). Treatment of extrahepatic manifestations of hepatitis C virus. Clinics in Liver Disease, 21(3), 631–643.CrossRefPubMed
3.
Juanbeltz, R., Zozaya, J. M., Reparaz, J., Castilla, J., Sarobe, M. T., Uriz Otano, J. I., et al. (2017). Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. Anales del Sistema Sanitario de Navarra, 40(1), 57–66.PubMed
4.
Juanbeltz, R., Goñi Esarte, S., Uriz-Otano, J. I., Martinez Echeverria, A., Elizalde, I., Zozaya, J. M., et al. (2017). Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine, 129(4), 476–483.CrossRefPubMed
5.
Kouris, G., Hydery, T., Greenwood, B. C., Lavitas, P., Price, M., Clements, K., et al. (2018). Effectiveness of Ledipasvir/Sofosbuvir and predictors of treatment failure in members with hepatitis C genotype 1 infection: A retrospective cohort study in a medicaid population. Journal of Managed Care and Specialty Pharmacy, 24(7), 591–597.CrossRefPubMed
6.
Honer Zu Siederdissen, C., Buggisch, P., Boker, K., Schott, E., Klinker, H., Pathil, A., et al. (2018). Treatment of hepatitis C genotype 1 infection in Germany: Effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterology Journal, 6(2), 213–224.CrossRefPubMedPubMedCentral
7.
Hezode, C. (2018). Treatment of hepatitis C: Results in real life. Liver International, 38(Suppl 1), 21–27.CrossRefPubMed
8.
San Miguel, R., Gimeno-Ballester, V., Blazquez, A., & Mar, J. (2015). Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 64(8), 1277–1288.CrossRefPubMed
9.
Jakobsen, J. C., Nielsen, E. E., Koretz, R. L., & Gluud, C. (2018). Do direct acting antivirals cure chronic hepatitis C? British Medical Journal, 361, k1382.CrossRefPubMed
10.
Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27(1), 209–212.CrossRefPubMed
11.
Bjornsson, E., Verbaan, H., Oksanen, A., Fryden, A., Johansson, J., Friberg, S., et al. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology, 44(7), 878–887.CrossRefPubMed
12.
Cordoba, J., Flavia, M., Jacas, C., Sauleda, S., Esteban, J. I., Vargas, V., et al. (2003). Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology, 39(2), 231–238.CrossRefPubMed
13.
Dusheiko, G. (2017). The impact of antiviral therapy for hepatitis C on the quality of life: A perspective. Liver International, 37(1), 7–12.CrossRefPubMed
14.
Juanbeltz, R., Martínez-Baz, I., San Miguel, R., Goñi-Esarte, S., Cabasés, J. M., & Castilla, J. (2018). Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE, 13(10), e0205277.CrossRefPubMedPubMedCentral
15.
San Miguel, R., del Villar, V., Perez, C., de Frutos, M., Mar, J., & Coma, M. J. (2010). Role of health-related quality of life measurements in the design of drug clinical trials. Farmacia Hospitalaria, 34(1), 16–22.CrossRefPubMed
16.
Miguel, R. S., Lopez-Gonzalez, A. M., Sanchez-Iriso, E., Mar, J., & Cabases, J. M. (2008). Measuring health-related quality of life in drug clinical trials: Is it given due importance? Pharmacy World and Science, 30(2), 154–160.CrossRefPubMed
17.
European Association for the Study of the Liver. (2018). EASL Recommendations on treatment of hepatitis C 2018. J Hepatol, 69(2), 461–511.CrossRef
18.
19.
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed
20.
Devlin, N. J., Parkin, D., & Browne, J. (2010). Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19(8), 886–905.CrossRefPubMed
21.
22.
Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24(2), 289–293.CrossRefPubMed
23.
Rothman, K., & Boice, J. D. (1979). Epidemiologic analysis with a programmable calculator. Washington, DC: U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health.
24.
Dean, A. G., Sullivan, K. M., Soe, M. M.. OpenEpi: Open source epidemiologic statistics for public health. (2013). Retrieved December 31, 2018, from https://​www.​OpenEpi.​com.
25.
Manuel, D. G., Schultz, S. E., & Kopec, J. A. (2002). Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the health utilities index. J Epidemiol Community Health, 56(11), 843–850.CrossRefPubMedPubMedCentral
26.
Fotos, N. V., Elefsiniotis, I., Patelarou, A., Giakoumidakis, K., Patelarou, E., Kouros, A., et al. (2018). Psychological disorders and quality of life among patients with chronic viral hepatitis: A single-center cross-sectional study with pair-matched healthy controls. Gastroenterology Nursing, 41(3), 206–218.CrossRefPubMed
27.
Hussain, K. B., Fontana, R. J., Moyer, C. A., Su, G. L., Sneed-Pee, N., & Lok, A. S. (2001). Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology, 96(9), 2737–2744.CrossRefPubMed
28.
Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45(3), 806–816.CrossRefPubMed
29.
30.
Younossi, Z. M., Stepanova, M., Feld, J., Zeuzem, S., Sulkowski, M., Foster, G. R., et al. (2017). Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 15(3), 421–430.e6.CrossRefPubMed
31.
Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Review of Gastroenterol and Hepatology, 11(3), 259–268.
32.
Younossi, Z. M., Stepanova, M., Henry, L., Nader, F., & Hunt, S. (2016). An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. The American Journal of Gastroenterology, 111(6), 808–816.CrossRefPubMed
33.
Ragusa, R., Bertino, G., Bruno, A., Frazzetto, E., Cicciu, F., Giorgianni, G., et al. (2018). Evaluation of health status in patients with hepatitis c treated with and without interferon. Health and Quality of Life Outcomes, 16(1), 17.CrossRefPubMedPubMedCentral
34.
Thein, H. H., Krahn, M., Kaldor, J. M., & Dore, G. J. (2005). Estimation of utilities for chronic hepatitis C from SF-36 scores. The American Journal of Gastroenterology, 100(3), 643–651.CrossRefPubMed
35.
Chong, C. A., Gulamhussein, A., Heathcote, E. J., Lilly, L., Sherman, M., Naglie, G., et al. (2003). Health-state utilities and quality of life in hepatitis C patients. The American Journal of Gastroenterology, 98(3), 630–638.CrossRefPubMed
36.
Van Rooijen, E. M., Hotho, D., Agthoven, M., Van Der Kolk, A., Hansen, B. E., Knegt, R., & Uyl-De Groot, C. A. (2011). The cost and quality of life of hepatitis C in the Netherlands. Value in Health, 14, A394. [Conference abstract].CrossRef
37.
Buchanan-Hughes, A. M., Buti, M., Hanman, K., Langford, B., Wright, M., & Eddowes, L. A. (2018). Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: A systematic literature review and meta-analysis. Quality of Life Research. https://​doi.​org/​10.​1007/​s11136-018-1992-3.CrossRefPubMed
38.
Lens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M. C., Llop, E., Martinez, J., et al. (2017). Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology, 153(5), 1273–1283.e1.CrossRefPubMed
39.
D’Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., et al. (2012). A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology, 56(2), 532–543.CrossRefPubMed
40.
Badia, X., Monserrat, S., Roset, M., & Herdman, M. (1999). Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Quality of Life Research, 8(4), 303–310.CrossRefPubMed
Metadaten
Titel
Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population
verfasst von
Regina Juanbeltz
Jesús Castilla
Iván Martínez-Baz
Aisling O’Leary
Maite Sarobe
Ramón San Miguel
Publikationsdatum
21.01.2019
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 6/2019
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02111-1

Weitere Artikel der Ausgabe 6/2019

Quality of Life Research 6/2019 Zur Ausgabe

OriginalPaper

Using health-related quality of life to predict cardiovascular disease events

OriginalPaper

Prevalence of mental health conditions and pain in adults with skeletal dysplasia

Review

Health-related quality of life among children, adolescents, and adults with bladder exstrophy–epispadias complex: a systematic review of the literature and recommendations for future research

Correction

Correction to: The impact of caregiver’s role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver’s disclosure of terminal disease status

OriginalPaper

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss

OriginalPaper

Association of nutritional status and health-related quality of life in children with chronic kidney disease

Premium Partner

    Bildnachweise